U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07094685) titled 'Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer' on July 23.
Brief Summary: This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Study Start Date: Sept. 01
Study Type: INTERVENTIO...